Evidence map›Paper›PMID 32015092›Full record

ArticleCancer research2020

Oncogenic ERG Represses PI3K Signaling through Downregulation of IRS2.

Ninghui Mao, Dong Gao, Wenhuo Hu, Sunyana Gadal, Haley Hieronymus, Shangqian Wang, Young Sun Lee, Patrick Sullivan, Zeda Zhang, Danielle Choi and 5 more

Abstract read
In one paragraph

Article in Cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. ETS factors in prostate cancer.Cancer letters · 2022
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Ninghui MaoHuman Oncogenesis and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Dong GaoHuman Oncogenesis and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Wenhuo HuHuman Oncogenesis and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-8686-7160
Sunyana GadalMolecular Oncology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Haley HieronymusHuman Oncogenesis and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Shangqian WangHuman Oncogenesis and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Young Sun LeeHuman Oncogenesis and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-6612-7341
Patrick SullivanHuman Oncogenesis and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-3784-4114
Zeda ZhangHuman Oncogenesis and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Danielle ChoiHuman Oncogenesis and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Neal RosenMolecular Oncology Program, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-8307-654X
Charles L SawyersHuman Oncogenesis and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-4955-6475
Anuradha GopalanDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Yu ChenHuman Oncogenesis and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Brett S CarverHuman Oncogenesis and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. carverb@mskcc.org.
Memorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
SPORE In Prostate CancerP50CA092629 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI JAMES A EASTHAM · 2001 to 2026
$63.0M
Studies on oncoprotein-induced feedback: Basic and therapeutic implicationsR35CA210085 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ROSEN, NEAL · 2016 to 2022
$7.3M
The MSKCC-UW/Fred Hutch Prostate Cancer Drug Resistance and Sensitivity CenterU54CA224079 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2017 to 2021
$6.8M
Patient-Derived Models of Prostate Cancer for Personalized MedicineU01CA224044 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CHEN, YU, FUTREAL, PHILLIP ANDREW · 2019 to 2023
$5.1M
Role of ETS factors in specifying prostate luminal cell identity and androgen receptor dependenceR01CA193837 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2015 to 2025
$4.7M
Understanding Resistance to Next Generation AntiandrogensR01CA155169 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2012 to 2022
$3.8M
Understanding the role of an aberrant hepatic nuclear transcription circuit in prostate cancer tumorigenesis and castration resistanceR01CA208100 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHEN, YU · 2017 to 2021
$2.5M
Defining Response and Resistance to PI3K and AR inhibition in Prostate CancerR01CA182503 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CARVER, BRETT STEWART · 2014 to 2018
$2.2M
Understanding the roles of TMPRSS2 and ERG in pathogenesis of prostate cancer.K08CA140946 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHEN, YU · 2009 to 2013
$796k
Howard Hughes Medical InstituteNCI NIH HHS K08 CA140946NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA092629NCI NIH HHS R01 CA155169NCI NIH HHS R01 CA182503NCI NIH HHS R01 CA193837NCI NIH HHS R01 CA208100NCI NIH HHS R35 CA210085NCI NIH HHS U01 CA224044NCI NIH HHS U54 CA224079
6 · The paper itself

Abstract

Genomic rearrangements leading to the aberrant expression of ERG are the most common early events in prostate cancer and are significantly enriched for the concomitant loss of PTEN. Genetically engineered mouse models reveal that ERG overexpression alone is not sufficient to induce tumorigenesis, but combined loss of PTEN results in an aggressive invasive phenotype. Here, we show that oncogenic ERG repressed PI3K signaling through direct transcriptional suppression of IRS2, leading to reduced RTK levels and activity. In accordance with this finding, ERG-positive human prostate cancers had a repressed AKT gene signature and transcriptional downregulation of IRS2. Although overexpression of IRS2 activated PI3K signaling, promoting cell migration in a PI3K-dependent manner, this did not fully recapitulate the phenotype seen with loss of PTEN as PI3K signaling is not as robust as observed in the setting of loss of PTEN. Importantly, deletions of the PTEN locus, which promotes active PI3K signaling, were among the most significant copy-number alterations that co-occurred with ERG genomic rearrangements. This work provides insight on how initiating oncogenic events may directly influence the selection of secondary concomitant alterations to promote oncogenic signaling during tumor evolution. SIGNIFICANCE: This work provides insight on how initiating oncogenic events may directly influence the selection of secondary concomitant alterations to promote tumorigenesis.

Indexed as

AnimalsCarcinogenesisCell Line, TumorDisease Models, AnimalDNA Copy Number VariationsDown-RegulationGene Expression Regulation, NeoplasticGene Knockdown TechniquesGene Knockout TechniquesGene RearrangementHumansInsulin Receptor Substrate ProteinsMaleMiceOncogene ProteinsPhosphatidylinositol 3-KinasesERG protein, humanERG protein, mouseInsulin Receptor Substrate ProteinsIRS2 protein, humanIrs2 protein, mouseOncogene ProteinsPhosphatidylinositol 3-KinasesPTEN PhosphohydrolasePTEN protein, humanPten protein, mouseTranscriptional Regulator ERG

Identifiers

PMID32015092
PMCPMC7127960
OpenAlexW3004414444

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.